Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.

Details

Language :

English

ISSN :

1523-1755

Volume :

99

Issue :

5

Database :

MEDLINE

Journal :

Kidney international

Accession number :

33892867

Full Text :

https://doi.org/10.1016/j.kint.2021.03.008